Preclinical evaluation of an unconventional ruthenium‐gold‐based chemotherapeutic: RANCE‐1, in clear cell renal cell carcinoma

BACKGROUND: There are few effective treatments for patients with advanced clear cell renal cell carcinoma (CCRCC). Recent findings indicate that ruthenium‐gold containing compounds exhibit significant antitumor efficacy against CCRCC in vitro affecting cell viability as well as angiogenesis and mark...

Descripción completa

Detalles Bibliográficos
Autores principales: Elie, Benelita T., Hubbard, Karen, Pechenyy, Yuriy, Layek, Buddhadev, Prabha, Swayam, Contel, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675714/
https://www.ncbi.nlm.nih.gov/pubmed/31192543
http://dx.doi.org/10.1002/cam4.2322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675714/
https://www.ncbi.nlm.nih.gov/pubmed/31192543
http://dx.doi.org/10.1002/cam4.2322

Ejemplares similares